65, quai Georges Gorse
33 1 58 33 50 00
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 5,072
|Mr. David Loew||MD, CEO & Director||2.38M||N/A||1967|
|Mr. Aymeric Le Chatelier||Exec. VP & Group CFO||N/A||N/A||1969|
|Dr. Aidan Murphy Ph.D.||Exec. VP of Technical Operations||N/A||N/A||1966|
|Mr. Craig Marks||Vice-Pres of Investor Relations||N/A||N/A||N/A|
|Mr. Francois Garnier||Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer||N/A||N/A||1962|
|Ms. Gwenan White||Exec. VP of Communications, Public Affairs & Sustainability||N/A||N/A||N/A|
|Mr. Regis Mulot||Exec. VP & Chief HR Officer||N/A||N/A||1966|
|Ms. Dominique Bery||Head of Nordics & Baltics||N/A||N/A||1971|
|Dr. Yan Moore M.D.||Sr. VP & Head of Oncology Therapeutic Area||N/A||N/A||1967|
|Dr. Alexander McEwan||Vice-Pres & Head of Radiopharmaceuticals||N/A||N/A||N/A|
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Ipsen S.A.’s ISS governance QualityScore as of 1 June 2023 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 7; Compensation: 6.